Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, thereby extending its spectrum of activity to include many beta-lactamase producing bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Febrile neutropenia (empiric treatment)
* Gynecologic infections
## Adult Dosing
* **Standard Dose:** 3.375 grams (3g piperacillin / 0.375g tazobactam) intravenously every 6 hours.
* **Higher Dose/Frequency (e.g., severe infections, hospital-acquired pneumonia, febrile neutropenia):** 4.5 grams (4g piperacillin / 0.5g tazobactam) intravenously every 6 or 8 hours.
* **Maximum Daily Dose:** Typically 18 grams (16g piperacillin / 2g tazobactam) per day, but can vary based on indication and institutional guidelines. Dosing is often based on the piperacillin component.
## Pediatric Dosing
Dosing in pediatric patients is complex and depends on age, weight, and indication. Consult specific pediatric guidelines or protocols.
* **Premature infants and term neonates:** Dosing is highly specialized and requires careful consideration of renal and hepatic function.
* **Pediatric patients > 12 weeks of age:** Dosing is typically calculated based on piperacillin weight-based dosage (e.g., 90-100 mg/kg piperacillin per dose given every 6-8 hours, with tazobactam proportionally dosed). The maximum dose should not exceed the adult maximum.
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Administer usual dose every 8 hours.
* CrCl < 20 mL/min: Administer usual dose every 12 hours.
* Hemodialysis: Administer usual dose every 12 hours and supplement with one additional dose during or after each dialysis session.
* **Hepatic Impairment:** No specific dose adjustment is typically required, but caution is advised.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation.
* History of a severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, constipation, abdominal pain, fever.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes, interstitial nephritis.
## Key Drug Interactions
* **Probenecid:** Increases and prolongs piperacillin-tazobactam plasma concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin; increased INR monitoring is recommended.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels.
* **Live bacterial vaccines:** Live vaccines should not be administered concurrently with piperacillin-tazobactam due to potential diminished immune response.
## Monitoring
* Renal function (CrCl) for dose adjustments.
* Liver function tests.
* Complete blood count (CBC) for hematologic effects (neutropenia, thrombocytopenia).
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *Clostridioides difficile*-associated diarrhea.
## Clinical Pearls
* Piperacillin-tazobactam is a broad-spectrum agent often reserved for more serious or complicated infections, or when resistance is a concern.
* Dosing frequency can be increased (e.g., every 4 hours) for critically ill patients to achieve higher target concentrations, especially for organisms with lower susceptibility. This is often guided by institutional protocols.
* For patients with severe renal impairment (CrCl < 20 mL/min) or on hemodialysis, dose reduction and/or increased frequency is necessary.
* Ensure adequate hydration to minimize the risk of crystalluria.
* Discontinue if a hypersensitivity reaction occurs.
***
*Disclaimer: This information is intended for clinical use and does not replace comprehensive drug information resources. Always consult the most current prescribing information and institutional protocols before administering any medication.*
